BioIVT continues biospecimen buy up with Keystone Biologicals deal

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Fly_dragonfly)
(Image: Getty/Fly_dragonfly)
The provider research models and services, BioIVT, has acquired Hatboro-PA-based Keystone Biologicals, which supplies disease-state plasma, sera, and controls.

BioIVT​ Vice President of Marketing Courtney Noah, PhD, said the acquisition broadens BioIVT’s capabilities in the in vitro diagnostics (IVD) space “by providing expanded control products and Keystone Biologicals’ expertise in the collection of bulk units of disease-state and normal sera and plasma.”

Following the transaction – financial terms of which were not disclosed – Keystone Biologicals will become part of the BioIVT organization.

With the addition, BioIVT will provide ‘comprehensive’ solutions, including remnant biofluids and tissues for early drug development, clinical specimens and point-of-care services for validation studies, and disease-state plasma collected as bulk units to support IVD manufacturing requirements, said Noah.

“When it comes to diagnostic kit development and manufacturing, IVD researchers need a reliable source for control and calibrator plasma and sera,”​ she added.

Little change will be seen in the early phases of integration, though as the companies fully merge, Noah said, “we will be looking to drive operational efficiencies and customer service processes that will serve to enhance the client experience.”

BioIVT – formerly BioreclamationIVT – has made several acquisitions over the last couple years, and standardized its site processes​ to manage clinical trial data at all of its locations.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more